In October 2008 the patient restarted topical imiquimod, this
time to his entire right abdomen. PET and CT scans in January
2009 showed partial resolution of the previously metabolically
active foci in the liver, and a decrease in size of the right iliac
fossa metastasis. At the time of his January 2009 scans, the patient
had been applying the imiquimod cream for approximately
six months: three months before his IL-2 treatment, and three
months afterward. Encouraged by the January 2009 scans, he
continued to apply topical imiquimod cream to his abdomen
and pelvis three times per week. Scans from September 2009
showed complete resolution of his hepatic lesions and a continued
decrease in the size of the right iliac fossa metastasis.
The patient’s most recent CT scans from December 2009 showed
no evidence of a hepatic mass and no continued growth of the
iliac fossa mass (Figures 3 and 4). Visual examination of the
patient’s abdomen and pelvic region in March 2010 showed
multiple red pustules approximately 8 mm in diameter concentrated
in the two regions he had been applying the imiquimod
cream (Figure 5). This was the only adverse effect of the imiquimod
treatment according to the patient.
DISCUSSION
Melanoma is a very aggressive and often fatal skin cancer,
and its incidence is rising worldwide. In the United States, the
incidence rate is 10–25 per 100,000.5 Risk factors for the development
of melanoma include having a large number of nevi
(especially dysplastic nevi), UV radiation and sun exposure,
immunosuppression, previous occurrence of melanoma and
having a family history of melanoma.7–8 The five-year survival
rate for patients with distant metastases is only 10 percent with
a median survival of six to 12 months.6
Spontaneous regression of melanoma metastases is extremely
rare. Spontaneous regression is defined as a complete or partial
disappearance of a metastatic lesion in the absence of therapy
—or in the presence of therapy that is considered inadequate to
yield significant tumor response. The incidence of spontaneous
regression of malignant melanoma is approximately one in 400
patients presenting with metastatic disease.9
This report describes a patient with stage IV melanoma, with
metastases to the stomach, liver, and iliac fossa. For patients
with stage IV melanoma, systemic chemotherapy is indicated,
despite its limited success.10 The choices for single-agent chemotherapy
include cytotoxic agents and cytokines.11 The above
patient received a single round of IL-2 monotherapy, which
has a response rate of 16–21.6 percent.6 Due to this patient’s
development of interleukin-induced myocarditis and the slow
progression of his lesions on multiple PET and CT scans, it was
decided that he would not undergo any more chemotherapy at
that time. On his own, the patient had started applying topical
imiquimod three times per week to a small area of abdominal